We are excited to share new pharmacological characterization data on our mas-related G-protein coupled receptor X2 (MRGPRX2) program at IMMUNOLOGY 2024, the Annual Meeting of the American Association of Immunologists in Chicago. As leaders in the development of MRGPRX2, we believe this new therapeutic class could play an important role in debilitating inflammatory diseases such as chronic spontaneous urticaria, atopic dermatitis and asthma. We will also present new important invitro and in-vivo pharmacology data on our Protein Kinase C Theta (PKCϴ) program. Please join us at the conference May 3-7 when we present our posters. https://lnkd.in/e7KwtVNk #AAI2024 #immunology #inflammation
Evommune’s Post
More Relevant Posts
-
Very interesting application of cytokine engineering for CAR-T in asthma. Pronounced and extended therapeutic activity in preclinical asthma model using single dose of CAR-T targeted to kill and disrupt eosinophils. Report in Nature Immunology with CAR-T cells using IL-5 anchored CD28 CD3 zeta construct for targeting, but also armored to secrete an IL-4 mutein that blocks IL-4/IL-13 signaling. #cytokine #celltherapy #drugdevelopment #immunotherapy #asthma #immunooncology.
A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice - Nature Immunology
nature.com
-
High-throughput in vivo LNP screening with molecular barcoding to explore LNP composition's impact on immune cell targeting for vaccines and therapies: https://lnkd.in/eta_zRf3
High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route
pubs.acs.org
-
Happy Thursday all! Check out this open access Opinions in Immunology review by Louisa F Alim, Colm Keane, Fernando Souza-Fonseca-Guimaraes, "Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment." Summary: Tumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either tumour elimination or progression. Here, we discuss the latest cutting-edge TNF-focused biologics currently in clinical translation that modifies the TME to derive greater immune responses and therapeutic outcomes, and further give perspectives on the future of targeting TNF in the context of cancer by emerging technological approaches. #drugdiscovery #tnf #inflammation #cancerresearch #immunooncology #immunotherapy #tme #scientificresearch #sciencecommunication
-
-
T cells in cell therapy
Hurdles impeding application of #γδTcells for #celltherapy. Although most γδ T cell subsets exhibit cytotoxicity against tumor cells, there exist pro-tumorigenic interleukin (IL)-17-producing (28) and PD-L1-overexpressing γδ T cells. These broadly termed regulatory γδ T cells (γδ Tregs) antagonize the therapeutic efficacy of cytotoxic γδ T cells and therefore suppress host immune responses. Interestingly, prior exposure or not to ligands during development in the murine thymus programs the effector fate of γδ T cells into respectively IFN-γ or IL-17-producing cells. The divergent roles of γδ T cell subsets in anti-tumor immunity have to be carefully delineated in order for their innate properties to be harnessed for immunotherapy. In the image: Whilst increasing amount of information is being discovered about γδ T cell biology (left panel), much remains to be further elucidated (right panel). Firstly, various subsets, including Vδ1 and Vδ2, have been identified. However, presence of substantial Vδ1 and Vδ2 populations suggest that continuous identification of additional subsets is warranted (point 1). Secondly, within each subset, the γδ T cells can be delineated by additional markers, such as CD56, CD27 and NKG2A. Identification of such additional markers will yield added insight into the functional roles of γδ T cells (point 2). Thirdly, while several molecules have been identified as ligands to the multitude of receptors on γδ T cells, many ligands recognized by TCRγδ or other surface receptors remain currently unidentified (point 3) Furthermore, the influence of the TME on the functions of γδ T cells has been established, but the exact conditions which tune γδ T cells towards pro- versus anti-tumor subsets are not yet well defined (point 4) Image from: https://lnkd.in/e-zmtkmy
-
-
I am an enthusiast of building every day a better version of myself that is humbly contributing to society by sharing and putting into practice my passion for advancing science and innovation
Check out our latest article on Immunology Equipment and industry trends. At Clinichain , we are committed to excellence - reach out for your clinical trial equipment needs. Have a great day!
Essential equipment for immunology studies in clinical trials In the rapidly advancing field of immunology, clinical trials play a pivotal role in exploring immune responses, testing vaccines, and developing innovative therapies like immunotherapy for diseases such as cancer, autoimmune disorders, and infectious diseases. For these studies to yield reliable results, specialized equipment is essential. Check our new article! #immunotherapy #Clinicaltrials #Clinicalequipment #medicaldevices ihttps://lnkd.in/e94HVwws
Essential Equipment for Immunology Studies in Clinical Trials
clinichain.com
-
Antibody CD-markers, also known as cluster of differentiation markers, play a pivotal role in immunology research and diagnostics. These markers are cell surface molecules that aid in identifying and classifying different types of immune cells based on their expression patterns. From T cells to B cells, dendritic cells to macrophages, CD-markers provide crucial insights into the complex landscape of the immune system. Curida Diatec proudly holds licensing rights for several excellent cell lines for producing antibody CD-markers. By targeting specific CD-markers with monoclonal antibodies, researchers can isolate, analyze, and manipulate distinct cell populations with precision and accuracy. In clinical settings, antibody CD-markers have transformative potential for disease diagnosis, prognosis, and treatment monitoring. They enable clinicians to identify abnormal immune cell populations associated with various disorders. Explore our portfolio of CD-markers below!
-
-
🌐 T-FINDER: Revolutionizing TCR and Ligand Discovery in Immunology 🔬 A new method in immunology research! "T-FINDER: A highly sensitive, pan-HLA platform for functional T cell receptor and ligand discovery" was recently published in Science Advances 🟠 Rapid identification of T cell receptors (TCRs) & their ligands, crucial in various diseases. 🟢 Decodes both CD4 & CD8 TCRs, targeting human leukocyte antigen (HLA) haplotypes. 🔵 Integrates a sensitive TCR signaling reporter with an advanced antigen processing system. 🟣 Identifies unknown peptide:HLA ligands from vast antigen libraries. 🟡 Unbiased, high-throughput platform, suitable for class II & I HLA-presented T cell epitopes 📚 Full article: https://buff.ly/43I0IaM 📢 Join the Conversation 📢 Share your thoughts, methods, and tools in the comments 👇 💬 #TCRDiscovery #ScienceAdvances #HealthcareInnovation #Bioinformatics
-
-
Check out my new paper published in Frontiers in Immunology! Thanks to everyone involved in getting this out! https://lnkd.in/ejSAyEDu
Frontiers | Targeted acidosis mediated delivery of antigenic MHC-binding peptides
frontiersin.org
-
PhD Student at Institut d’Investigacions Biomèdiques August Pi i Sunyer thanks to a Doctoral INPhINIT Fellowship @BecariosFLC
I am glad to announce that our article titled "Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for Type 1 Diabetes" has been published in the Journal of Autoimmunity. Autoimmune diseases, including Type 1 Diabetes, arise from a breakdown in immunological tolerance in which antigen-presenting cells play a pivotal role. These diseases present a significant challenge, affecting millions of people worldwide. It is therefore necessary to broaden our understanding of the specific characteristics of their pathology to develop future effective treatments. In this study, we delve into potential therapeutic avenues by investigating the functional and phenotypic characteristics of macrophages (MoMø) in individuals with T1D, along with the effects of PS-liposome preclinical immunotherapy. We first demonstrate that the efferocytic ability of MoMø of adult T1D subjects is not impaired in vitro, and then dissect their phenotypic particularities. Further, our results revealed the selective impact of PS-liposomes on inflammatory M1 macrophages in terms of cytokine release and ability to trigger T cell proliferation providing new data on the mechanism of action behind their tolerogenic effect. Thanks to all the team! And in particular to David Perna Barrull and Marta Vives Pi. Now go check the full article! https://lnkd.in/dS68eiAG #Autoimmunity #Type1Diabetes #Tolerance #Immunotherapy #Research #Macrophages #Immunology
Targeting macrophages with phosphatidylserine-rich liposomes as a potential antigen-specific immunotherapy for type 1 diabetes
sciencedirect.com
-
Repurposing CAR T Therapies 🌟🧬 Exciting breakthrough from Min Peng, PhD, and his team at Tsinghua University: using CAR T technology to treat chronic asthma in a mouse model. Their study in Nature Immunology shows that a single infusion of engineered CAR T cells can induce long-term remission of asthma, providing a proof of concept for non-cancerous applications of CAR T therapy. This could revolutionize treatment for chronic diseases, demonstrating the potential for CAR T cells to address conditions beyond cancer. 📝Read more here: https://lnkd.in/eXgUw2r3 #CART #AsthmaResearch #Biotechnology #ESACTUK
A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice - Nature Immunology
nature.com
